Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
21.89
+0.76 (3.60%)
At close: Sep 2, 2026, 4:00 PM EDT
21.80
-0.09 (-0.41%)
Pre-market: Sep 3, 2026, 7:08 AM EDT
Legend Biotech Employees
Legend Biotech had 2,965 employees as of December 31, 2025. The number of employees increased by 356 or 13.65% compared to the previous year.
Employees
2,965
Change (1Y)
356
Growth (1Y)
13.65%
Revenue / Employee
$428,803
Profits / Employee
-$30,860
Market Cap
4.24B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,965 | 356 | 13.65% |
| Dec 31, 2024 | 2,609 | 783 | 42.88% |
| Dec 31, 2023 | 1,826 | 436 | 31.37% |
| Dec 31, 2022 | 1,390 | 319 | 29.79% |
| Dec 31, 2021 | 1,071 | 189 | 21.43% |
| Dec 31, 2020 | 882 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Iovance Biotherapeutics | 975 |
| Arcus Biosciences | 601 |
| Dyne Therapeutics | 289 |
| Relay Therapeutics | 202 |
| Celcuity | 155 |
| IDEAYA Biosciences | 145 |
| Edgewise Therapeutics | 127 |
LEGN News
- 1 day ago - Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 17 days ago - Legend Biotech price target lowered to $24 from $29 at TD Cowen - TheFly
- 17 days ago - Legend Biotech price target lowered to $78 from $80 at Barclays - TheFly
- 17 days ago - Legend Biotech downgraded to Perform from Outperform at Oppenheimer - TheFly
- 17 days ago - Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs - TheFly
- 17 days ago - Legend Biotech price target raised to $49 from $48 at Morgan Stanley - TheFly
- 22 days ago - Legend Biotech Earnings Call Transcript: Q2 2026 - Transcripts
- 22 days ago - Legend Biotech Earnings release: Q2 2026 - Filings